Shervin Pishevar Warns Of Changes Coming To The American Economy

Business, CEO, Entrepreneur, Investment, Technology

There is something brewing in the United States that we have not seen in our lifetimes if you believe the words of Shervin Pishevar. He feels that we going through a transformative time in the country that is going to shape the way that we all move forward into the future.

As an early investor in Uber, Shervin Pishevar earned a name for himself by being one of the first to put his faith and his money into the company. He not only earned a good reputation for having done this, but he also earned himself a nice bit of money as well. He proved that he knew how to make a good financial prediction.

Twitter has been blessed by the likes of Shervin Pishevar. He has an account that he likes to use frequently in order to inform his readers of his thoughts on how things are going in the economy. He even recently took the opportunity to go on a “tweet storm”. This is a stretch of time during which a person uses their Twitter account to send out multiple messages on the same or similar topics.

The tweet storm from Shervin Pishevar would end up lasting a total of fifty tweets over a period of twenty-one hours. Thus, he was able to keep his followers hanging on his every word the whole time.

During that lengthy amount of time he tweeted about how he feels that the stock market is about to go into a correction. That is when the market corrects by at least twenty percent. That kind of thing is common enough, but the reasons why Shervin Pishevar believes that it is about to happen are something different.

He thinks that China and others are becoming the parts of the world where the newest startups are going to happen. Instead of great companies getting their start in America we will have to look abroad as other countries start to take away the biggest advantage that we used to have over them. He may or may not be right about this, but at least he has a strong track record of predictions from the past.

https://b612foundation.org/members/shervin-pishevar/

Sahm Adrangi Issues Report on Pharma Company

Business, Business Leader, CEO, Financial, Financial Advice, Investment Advice, Investor

When you are looking to invest your personal capital, doing the right level of financial diligence is very important. While most people focus on reading reports about companies that discuss their future growth potential, other people and up researching companies that have potential for big losses.

When looking for opportunities that could result in a company losing stock value, you could end up making a lot of money through short selling and buying put options. One individual that continues to provide insight into companies that may have overvalued stocks is Sahm Adrangi, who is the principal of Kerrisdale Capital.

Over the past few years, Sahm Adrangi has issued a number of very insightful reports that discussed the financial condition of many different companies. While many of his views end up being disputed, he is often proven correct in his assessment. Over the past few weeks, Sahm Adrangi issued a report on the prospects of Proteostasis Therapeutics.

Overall, Sahm Adrangi gave a number of good reasons why he thinks the company will not continue to see a high stock price. Overall, the future prognosis of Proteostasis Therapeutics will hinge on the company’s ability to bring a new drug they are working on to the next stage of a clinical trial. The Proteostasis Therapeutics company was recently able to bring a drug used to treat cystic fibrosis through Stage 2 testing with the FDA. While this is a major accomplishment, there is still a lot more work that needs to be done in order for them to be able to bring it to market. While Proteostasis Therapeutics has seen a big increase in value due to the Stage 2 test, the company could suffer if it is not successful in bringing it through Stage 3.

According to Adrangi, there is plenty of reason to doubt that Proteostasis Therapeutics will be able to bring their next drug through the next stage of clinical trials. He also believes that the company has tried to stay compliant by producing interim reports, but he believes that a lot of the information provided has been swept under the rug.

http://www.businessinsider.com/meet-hedge-funder-sahm-adrangi-2013-10